Ascendis Pharma A (ASND) Long-Term Debt Repayments (2023 - 2026)
Ascendis Pharma A (ASND) posted Long-Term Debt Repayments of -$10.0 million for Q1 2026, down 26.27% sequentially from -$8.0 million in Q4 2025, and down 211.47% YoY from $9.0 million in Q1 2025.
Ascendis Pharma A (ASND) Long-Term Debt Repayments (2023 - 2026) Analysis & Trends
Ascendis Pharma A has reported Long-Term Debt Repayments for 4 years, with the latest figure at -$10.0 million in Q1 2026.
- Quarterly Long-Term Debt Repayments fell 211.47% year-over-year to -$10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.9 million (down 155.16% YoY) and the FY2025 annual result came in at -$25.6 million, down 110.46% from the prior year.
- Long-Term Debt Repayments slipped to -$10.0 million in Q1 2026 per ASND's latest filing, from -$8.0 million in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at -$2.7 million in Q2 2023 and troughed at -$10.0 million in Q1 2026.
- A 4-year average of -$4.5 million and a median of -$3.1 million in 2024 frame the typical range for Long-Term Debt Repayments.
- The sharpest annual moves came in 2025 and 2026: Long-Term Debt Repayments fell 6.56% in 2025, then sank 211.47% in 2026.
- Over 4 years, Long-Term Debt Repayments stood at -$2.9 million in 2023, then dropped by 7.02% to -$3.1 million in 2024, then plunged by 152.61% to -$8.0 million in 2025, then decreased by 26.27% to -$10.0 million in 2026.
- According to Business Quant data, Long-Term Debt Repayments over the past three periods registered -$10.0 million, -$8.0 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 17.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -10.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.04 Mn |
| Mar 31, 2026 | -10.04 Mn |
| Dec 31, 2025 | -7.96 Mn |
| Dec 31, 2025 | -7.96 Mn |
| Sep 30, 2025 | -7.68 Mn |
| Sep 30, 2025 | -7.68 Mn |
| Jun 30, 2025 | -6.21 Mn |
| Jun 30, 2025 | -6.21 Mn |
| Mar 31, 2025 | -3.23 Mn |
| Mar 31, 2025 | -3.23 Mn |
| Dec 31, 2024 | -3.15 Mn |
| Dec 31, 2024 | -3.15 Mn |
| Sep 30, 2024 | -3.09 Mn |
| Sep 30, 2024 | -3.09 Mn |
| Jun 30, 2024 | -3.04 Mn |
| Jun 30, 2024 | -3.04 Mn |
| Mar 31, 2024 | -3.03 Mn |
| Mar 31, 2024 | -3.03 Mn |
| Dec 31, 2023 | -2.94 Mn |
| Dec 31, 2023 | -2.94 Mn |